v3.25.1
Condensed Statements of Cash Flows (unaudited) - USD ($)
9 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Cash Flows from Operating Activities    
Net Loss $ (2,693,100) $ (3,222,216)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization 331,719 414,177
Stock-based compensation expense (38,174) 760,738
Warrants issued for underwriting fee 95,984
Changes in operating assets and liabilities which used cash:    
Accounts receivable 25,620 15,000
Prepaid expenses and other current assets 227,768 (73,476)
Accounts payable (17,970) (7,063)
Accrued compensation 133,799 (900)
Deferred revenue 3,835 (52,083)
Other accrued liabilities (85,285) 6,459
Net cash and cash equivalents used in operating activities (2,015,804) (2,159,364)
Cash Flows from Investing Activities    
Purchase of property and equipment (1,166)
Investment in capitalized software (292,199) (227,600)
Net cash and cash equivalents used in investing activities (292,199) (228,766)
Cash Flows from Financing Activities    
Proceeds from the sale of common stock 3,095,950
Net cash and cash equivalents provided by financing activities 3,095,950
Net increase (decrease) in cash, cash equivalents, and restricted cash 787,947 (2,388,130)
Cash, cash equivalents, and restricted cash - Beginning of period 2,171,016 5,360,661
Cash, cash equivalents, and restricted cash - End of period 2,958,963 2,972,531
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:    
Settle restricted stock units through common stock issuance to directors 600,000
Issuance of common stock for accrued director compensation 21,890
Issuance of common stock for public offering consulting expenses $ 655,000  

Source